MedPath

Fecal Microbiota Transplantation for Epilepsy

Phase 2
Recruiting
Conditions
Epilepsy
Interventions
Registration Number
NCT02889627
Lead Sponsor
The Second Hospital of Nanjing Medical University
Brief Summary

Increasing evidences showed the microbiota effects on neuropsychiatric disorders. This clinical trial aims to evaluate the efficacy and safety of fecal microbiota transplantation for epilepsy.

Detailed Description

Very few literatures reported the clinical use of microbiota or bacteria for brain diseases. The most effective strategy for reconstruction of gut microbiota should be fecal microbiota transplantation (FMT). This study aims to evaluate the efficacy and safety of FMT for epilepsy. Patients were diagnosed as epilepsy by electroencephalogram (EEG) and MRI and clinical data when the study began and thent received repeated FMT with fecal from healthy donors.The antiepileptic medication regimen of patients remained unchanged after FMT. The primary outcome measure was the frequency of the seizures. Secondary outcome measure were the 50% response rate.

.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria

had been diagnosed with epilepsy for at least three months; experienced at least one seizure during the three months before WMT ;

Exclusion Criteria

had other severe diseases, including other intestinal disorders (e.g., Clostridioides difficile infection), malignant neoplasm, cardiopulmonary failure or serious liver or kidney disease, had undergone previous FMT or WMT, had taken antibiotics within three months before starting WMT

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
FMT with microbiota suspensionFecal microbiota suspensionParticipants undergo repeated FMT with \~50ml microbiota suspension.
Primary Outcome Measures
NameTimeMethod
Frequency of the seizures3months

the rates of patients who achieved a ≥50% reduction in seizure frequency from baseline to one month after WMT

Secondary Outcome Measures
NameTimeMethod
gut microbiota analysisbaseline, 1 week-post-FMT, 1 months-post-FMT, 3 months-post-FMT

The stool samples of participants before and after FMT were collected and analized, by 16S rRNA and were used to investigate the crucial microbiota for devising a more efficient treatment strategy for epilepsy.

Adverse events3months

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after FMT.

Trial Locations

Locations (1)

Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath